Premium
Specialist‐based treatment reduces the severity of allergic rhinitis
Author(s) -
Mullol J.,
Bartra J.,
Cuvillo A.,
Izquierdo I.,
MuñozCano R.,
Valero A.
Publication year - 2013
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/cea.12081
Subject(s) - medicine , quality of life (healthcare) , asthma , nasal administration , prospective cohort study , observational study , severity of illness , corticosteroid , immunology , nursing
Summary Background Although the treatment of allergic rhinitis ( AR ) is now well established, its impact on severity has not yet been evaluated. Objective The aim was to analyse specialist‐based treatment on AR severity, nasal symptoms and quality of life. Methods A longitudinal observational, prospective, multi‐centre study with 4 weeks of follow‐up was carried out by 141 allergologists and ENT specialists in Spain. Selection criteria were adult patients with AR , clinically diagnosed at least 2 years before, with a total nasal symptom score ( TNSS ) ≥5, not receiving either antihistamines within the previous week or nasal corticosteroids during the 2 previous weeks. Disease severity using both original Allergic Rhinitis and its Impact on Asthma (o‐ ARIA ) and modified (m‐ ARIA ) classifications, nasal symptoms, and Quality of Life ( ESPRINT ‐15), were measured at baseline and after 4 weeks of treatment. Results Among the recruited AR patients ( n = 707, 58% women), 39.3% were intermittent and 60.7% persistent, 40.2% had asthma and 61.4% conjunctivitis. Most patients were treated with second generation antihistamines in monotherapy (63.2%) or in combination with intranasal corticosteroids (31.5%). While using o‐ ARIA , 96.9% of patients had ‘moderate/severe’ AR , the m‐ ARIA discriminated between ‘moderate’ (55.4%) and severe (41.5%) AR , at baseline. After 4 weeks of treatment, improvement was found on disease severity ( P < 0.0001), TNSS (8.2 ± 1.8 vs. 3.5 ± 2.3, P < 0.0001) and Quality of Life ( ESPRINT ‐15 global score: 3.0 ± 1.2 vs. 1.1 ± 1.0, P < 0.0001). Conclusions Specialist‐based treatment reduces AR severity, evaluated using the m‐ ARIA classification for the first time, in addition to the improvement of nasal symptoms and quality of life. Clinical relevance Specialist‐based treatment improves AR severity, in addition to nasal symptoms and quality of life. However, no matter the treatment option some AR patients remain severe and need further follow‐up.